Catalog No.
Product Name
Application
Product Information
Citations
-
Prekallikrein synthesis reducer
Onvuzosiran is a small interfering RNA (siRNA) that effectively reduces the synthesis of prekallikrein, a key component in the contact activation pathway of blood coagulation. By targeting and silencing the gene responsible for prekallikrein production, Onvuzosiran plays a crucial role in research focused on thrombosis, inflammatory responses, and related cardiovascular disorders. This reagent is essential for studies investigating the modulation of the coagulation cascade and the development of novel therapeutic strategies. -
FXIa/Kallikrein Inhibitor
FXIa/Plasma kallikrein-IN-1 is a potent inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein, exhibiting Ki values of 187.70 nM and 151.6 nM, respectively. This compound serves as a valuable tool for investigating thromboembolic diseases and related disorders. Its selective inhibition of these targets can facilitate the exploration of pathological mechanisms and the development of therapeutic strategies for coagulopathies. -
Plasma Kallikrein Inhibitor
Plasma kallikrein-IN-3 is a potent inhibitor of plasma kallikrein, exhibiting an IC50 of 0.15 μM. This compound is relevant for research into hereditary angioedema, diabetic macular edema, and diabetic retinopathy. Its selective inhibition of plasma kallikrein supports investigations into related pathophysiological processes and therapeutic interventions. -
Protease Inhibitor
ONO-3307 is a potent protease inhibitor that acts competitively against a range of proteases, including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. This compound has demonstrated efficacy in alleviating endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rat models. ONO-3307 is valuable for research into thrombosis and various protease-mediated diseases, providing insights into potential therapeutic strategies. -
PKK Inhibitor
Donidalorsen is an antisense oligonucleotide that selectively targets prekallikrein (PKK). By binding to and degrading PKK mRNA in the liver, Donidalorsen effectively inhibits kallikrein activity and reduces bradykinin production. This reagent is valuable for research focused on hereditary angioedema and related pathophysiological studies. -
KLK6 Inhibitor
DKFZ-251 is an inhibitor of the kininogenase-related peptidase KLK6, demonstrating an IC50 of 0.47 μM. It also shows inhibitory activity against KLK5 and KLK7 with IC50 values of 1.1 nM and 73 nM, respectively. This compound functions by transiently acylating the catalytic serine of KLK6, resulting in a stable acyl-enzyme complex that effectively inhibits enzymatic activity. DKFZ-251 serves as a phenotypic modulator, impacting cell proliferation and regulating epithelial-mesenchymal transition (EMT), making it a valuable tool in studies related to head and neck cancer. -
Kallikrein Inhibitor
KKI-5 is a selective inhibitor of tissue kallikrein, demonstrating significant activity in reducing breast cancer cell invasion. This compound is valuable for research into cancer biology and the mechanisms of metastasis, offering insights into potential therapeutic strategies targeting kallikrein-related pathways. -
Target Protein Ligand
LAG-3 degrader 1 is a PROTAC target protein ligand designed for the synthesis of PROTACs targeting LAG-3. This compound facilitates the targeted degradation of LAG-3, demonstrating significant anti-tumor activity. It serves as a valuable tool in cancer research, allowing for the exploration of LAG-3 modulation in therapeutic applications. -
LAG-3 Ligand
LAG-3 biner 1 is a small molecule ligand that specifically targets the immune checkpoint lymphocyte activation gene 3 (LAG-3), exhibiting a Kd of 1.23 μM. This compound plays a significant role in modulating immune responses and is valuable for research applications focused on cancer diagnostics and the exploration of immune regulation involving LAG-3. -
LAG-3/MHCII and LAG-3/FGL1 PPI Inhibitor
SA-15-P is a potent inhibitor of the LAG-3/MHCII and LAG-3/FGL1 protein-protein interactions, with IC50 values of 4.21 μM and 6.52 μM, respectively. By disrupting these interactions, SA-15-P serves as a valuable tool in immunotherapy research, providing insights into immune regulation and the potential enhancement of anti-tumor responses. Its application facilitates the exploration of therapeutic strategies targeting LAG-3 in various disease contexts. -
LAG-3 Inhibitor
LAG-3-IN-2 is a selective inhibitor of LAG-3 (Lymphocyte Activation Gene 3), a key immune checkpoint involved in the regulation of T cell responses. By blocking LAG-3, this compound enhances T cell activation and proliferation, making it a valuable tool in immunological research. It is particularly relevant in studies focused on cancer immunotherapy and autoimmune diseases, where modulation of immune responses is critical. -
LAG-3 D1 Ligand
Z3071585108 is a small molecule inhibitor of the LAG-3 D1 domain, exhibiting Kd values of 59.2 μM and 56.1 μM through MST-TRIC channel and spectral shift detection, respectively. This compound partially inhibits the interaction between LAG-3 and MHC class II molecules, with an EC₅₀ value of 42.9 μM. Z3071585108 is valuable for research on small molecule immunotherapies targeting the LAG-3 pathway, contributing to the understanding of immune modulation in various diseases. -
Bioactive Peptide
OVA-T4 Peptide (SIITFEKL) is a bioactive peptide variant of the ovalbumin epitope (OVA (257-264)), known for its binding to H-2Kb MHC class I molecules. This peptide exhibits comparable binding strength to H-2Kb but demonstrates significantly reduced affinity for the OT-I TCR. OVA-T4 Peptide is useful in research focused on T cell responses and MHC-TCR interactions, making it valuable for the study of immunological mechanisms and peptide-MHC complex dynamics. -
Peptide
OVA peptide is a class I (Kb)-restricted peptide epitope derived from ovalbumin, associated with the major histocompatibility complex (MHC) molecule H-2Kb in mice. This peptide plays a crucial role in immune response studies, particularly in allergy research, where it serves as a model antigen. Its ability to elicit specific T cell responses makes OVA peptide a valuable tool for understanding immune mechanisms and developing therapeutic strategies in allergy and immunology. -
Polypeptide
Gp100 (25-33), human is a polypeptide fragment comprising amino acids 25-33 of the human melanoma antigen. This 9-amino acid epitope is restricted by MHC class I H-2Db and elicits a specific T cell response due to its immunogenic properties. Gp100 (25-33), human is valuable for cancer research, particularly in studies focused on melanoma and T cell-mediated immune responses. -
KRAS[G13C](ON) Inhibitor
RM-041 is a selective, orally active inhibitor targeting KRAS[G13C](ON), forming a covalent complex with both KRASG13C (ON) and Cyclophilin A. This compound effectively blocks the binding of RAS effector proteins through steric hindrance and irreversibly binds to Cys-13, leading to the inhibition of KRASG13C mutant cancer cell proliferation. RM-041 demonstrates significant regression of KRASG13C tumors in both cellular and xenograft tumor models and exhibits a synergistic effect in combination with upstream inhibitors, such as SHP2 inhibitors. It serves as a valuable research tool in studying non-small cell lung cancer. -
TCIP 1 Ligand
BCL6-IN-13 is a potent inhibitor of the B-cell lymphoma 6 (BCL6) protein, demonstrating an IC50 value of 2 nM. This compound disrupts the interaction between BCL6 and its target proteins, leading to the activation of transcription factors involved in cellular growth and differentiation. BCL6-IN-13 is primarily utilized in research focused on B-cell malignancies, autoimmune disorders, and understanding the molecular mechanisms underlying oncology-related transcription regulation. -
BCL6 Degrader
BMS-986458 is a selective cereblon-based BCL6 degrader that exerts antitumor effects through the targeted degradation of the BCL6 protein. By binding to cereblon and interacting with the BTB domain of BCL6, it modulates key pathways such as cell cycle regulation, antiproliferative signals, and interferon responses, while also enhancing CD20 expression and distribution. BMS-986458 influences follicular helper T cell physiology and reduces circulating tumor DNA levels. Its combination with CD20xCD3 bispecific antibodies has been shown to improve T cell infiltration and expansion in tumors. This compound is applicable in research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma. -
PROTAC BCL6 Degrader
PROTAC BCL6 Degrader-3 is a selective degrader targeting the BCL6 protein through the proteolysis-targeting chimera (PROTAC) approach. This compound mediates the ubiquitination and subsequent degradation of BCL6, facilitating the modulation of pathways associated with cancer and autoimmune diseases. It serves as a valuable tool for researchers exploring therapeutic strategies aimed at BCL6 inhibition and the underlying mechanisms of related diseases. -
BCL6 Inhibitor
CCT374705 is a potent BCL6 inhibitor with an IC50 value of 4.8 nM, demonstrating significant antiproliferative effects in vitro. This compound effectively inhibits tumor growth in lymphoma xenograft mouse models, making it a valuable reagent for investigating BCL6-related pathways in cancer research and potential therapeutic applications. -
EWSR1::FLI1 Binder
EB-TCIP is an EWSR1::FLI1 binder that operates by forming a ternary complex with the tagged fusion protein BCL6 and FKBP12F36V. This compound specifically recruits the EWSR1::FLI1 fusion to BCL6-associated DNA regions, leading to chromatin remodeling and the relocalization of transcriptional factors. As a result, EB-TCIP activates the expression of previously repressed BCL6 target genes. It serves as a valuable tool in the exploration of innovative epigenetic therapies for Ewing sarcoma. -
BCL6 Inhibitor
BCL6-IN-6 is a selective inhibitor targeting the transcriptional repressor B-cell lymphoma 6 (BCL6). It effectively disrupts the interaction between BCL6 and its corepressors, leading to the reactivation of BCL6 target genes in a dose-dependent manner. This compound is particularly relevant for studies focusing on diffuse large B-cell lymphoma (DLBCL) and related oncogenic pathways. -
BCL6 Inhibitor
GSK137 is a potent and selective inhibitor of B-cell lymphoma 6 (BCL6), acting primarily by disrupting the interaction between BCL6 and corepressors such as SMRT. This mechanism results in a reduction of germinal center B cells, making GSK137 a valuable tool for investigating autoimmune diseases, including systemic lupus erythematosus (SLE), and B-cell malignancies, such as diffuse large B-cell lymphoma. Its oral bioactivity aids in the exploration of therapeutic strategies targeting these conditions. -
BCL6 Inhibitor
BCL6-IN-11 is a potent BCL6 inhibitor that disrupts the interaction between BCL6 and its co-inhibitory proteins, such as NCOR1, with an IC50 value of 6 nM. This compound induces approximately 52% degradation of BCL6 at a concentration of 5 μM over 90 minutes, classifying it as a partial degrader. BCL6-IN-11 is valuable for research applications in studying lymphoma and the role of BCL6 in oncogenesis. -
BCL6 Inhibitor
WK692 is a potent inhibitor of BCL6, specifically targeting the BCL6 BTB/SMRT interaction. This compound demonstrates significant biological activity by effectively inhibiting the growth of diffuse large B-cell lymphoma cells. Furthermore, WK692 has been shown to synergize with EZH2 and PRMT5 inhibitors, making it a valuable tool for research into targeted cancer therapies and the mechanistic understanding of lymphoma progression. -
BCL-6 PROTAC Degrader
BCL6-760 is an orally active BCL-6 PROTAC degrader that selectively targets and degrades BCL-6 with an EC50 of 0.8 nM, without affecting other CRBN substrates. This compound exhibits notable efficacy in orthotopic xenograft mouse models of OCI-LY-1 tumors. BCL6-760 serves as a valuable tool for investigating diffuse large B-cell lymphoma (DLBCL) and for exploring mechanisms related to BCL-6 signaling pathways in cancer research. -
BCL6 PROTAC
BCL6 PROTAC 1 is a selective proteolysis targeting chimera (PROTAC) that targets B-cell lymphoma 6 (BCL6) for degradation. It exhibits potent inhibitory activity on BCL6 cell reporter assays, with an IC50 value of 8.8 µM. This reagent effectively induces degradation of BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it a valuable tool for tumor-related research applications. -
BCL6 Ligand
BCL6 ligand-8 is a bifunctional linker designed to target the BCL6 protein for degradation via the PROTAC (Proteolysis Targeting Chimeras) mechanism. This compound plays a crucial role in the synthesis of PROTACs, including the effective BCL6-760, known for its anti-tumor properties. BCL6 ligand-8 is primarily utilized in cancer research to explore therapeutic strategies involving protein degradation pathways. -
BCL6 Inhibitor
BCL6-IN-10 is a selective molecular glue inhibitor that targets the BTB domain of BCL6, exhibiting an IC50 of 4 nM. This compound demonstrates significant anti-proliferative activity in diffuse large B-cell lymphoma (DLBCL) cell lines, making it a valuable tool in cancer research. Its unique mechanism of action offers insights into therapeutic strategies for targeting BCL6-associated malignancies. -
BCL6 Ligand
BCL6 ligand-4 is a selective ligand targeting BCL6, a key regulator of oncogenic transcription. This compound is primarily utilized in the synthesis of PROTACs, enabling targeted protein degradation for therapeutic applications in oncology research. BCL6 ligand-4 provides researchers with essential tools to explore BCL6-related pathways and develop innovative cancer treatments. -
BCL6 Inhibitor
SMRT peptide is a BCL6 inhibitor that functions by binding to the BTB domain of BCL6, thereby enhancing its transcriptional repression activity. This compound serves as a valuable tool for studying protein-protein interactions related to BCL6 function in various biological processes. Research applications include investigations into the role of BCL6 in cancer and other diseases where transcriptional regulation is critical. -
BCL6 Ligand
BCL6 ligand-5 is a selective ligand for the BCL6 protein, involved in transcriptional regulation and oncogenesis. This compound serves as a crucial component for the development of PROTAC-based degraders targeting BCL6, such as PROTAC BCL6 Degrader-2. Additionally, BCL6 ligand-5 has applications in tumor research, contributing to the study of cancer biology and therapeutic strategies. -
BCL6
OICR11029 is a selective inhibitor of BCL6, a transcriptional repressor implicated in various cancers. This compound demonstrates significant efficacy in disrupting BCL6 function, making it a valuable tool for investigating its role in tumorigenesis. OICR11029 is particularly useful for research focused on lymphoma and related hematological malignancies. -
Anti-CD19/CD3ε/Albumin Antibody
Faziprumig is a monoclonal antibody that targets CD19, CD3ε, and human serum albumin, exhibiting dissociation constants (Kd) of 0.0738 nM, 7.997 nM, and 0.6 nM, respectively. This reagent effectively activates T cells, leading to their lysis, and demonstrates significant efficacy in targeting and eliminating B-cell malignancies with low CD19 expression. Faziprumig is particularly relevant in the research of non-Hodgkin's lymphoma and various B-cell malignancies. -
CD19/4-1BB Antibody
Englumafusp alfa is a CD19/4-1BB antibody construct designed to enhance immune response by promoting CD19-specific cross-linking of the 4-1BB receptor on T and NK cells. This fusion protein consists of a CD19-specific antibody domain linked to trimerized extracellular domains of human 4-1BB ligand (41BBL). Its key biological activity supports investigations into immuno-oncology applications, particularly in targeting CD19-positive malignancies. Researchers can utilize Englumafusp alfa to study T cell activation and proliferation in the context of cancer therapies. -
Anti-CD19 Monoclonal Antibody
GBR-401 is a humanized anti-CD19 monoclonal antibody that targets CD19 with high affinity for FcγRIIIa. It exhibits potent cytotoxic activity against B-cell malignancies through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and direct cell killing. GBR-401 is effective in depleting malignant B cells and has been shown to prolong survival in various xenograft models using severe combined immunodeficiency (SCID) mice, making it a valuable tool for cancer research and therapeutic development. -
CD2 mAb
BTI-322 is a human IgG1κ monoclonal antibody targeting the CD2 antigen expressed on T cells and natural killer (NK) cells. This reagent demonstrates potent immunosuppressive activity by effectively inhibiting T cell proliferation in response to alloantigens in vitro. BTI-322 is known to recognize a majority of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias, making it suitable for applications in research on renal allograft rejection and steroid-refractory acute graft-versus-host disease. Additionally, BTI-322 serves as a valuable tool for T-cell depletion studies in various immunological contexts. -
Anti-MS4A1/CD20 Monoclonal Antibody
Blidarvetug is a monoclonal antibody that targets MS4A1/CD20, specifically designed for veterinary applications. This reagent is utilized in the investigation of CD20-positive B-cell lymphoma in canine models, facilitating research into the pathophysiology and treatment strategies for this particular type of cancer. Its specificity for CD20 offers valuable insights into B-cell malignancies in veterinary oncology. -
CD20xCD3 Antibody
Imvotamab is a bispecific immunoglobulin M (IgM) antibody targeting CD20 and CD3. It induces T cell activation while preventing excessive stimulation and potential down-regulation of immune responses. This dual-action mechanism makes Imvotamab a valuable tool for research on B-cell malignancies, including multiple myeloma and non-Hodgkin's lymphoma, facilitating studies on immune modulation and therapeutic interventions. -
Anti-CD20 Antibody
BLX-301 is a humanized monoclonal antibody that targets CD20 on B cells. It demonstrates robust anti-tumor activity, making it a valuable tool for research in non-Hodgkin lymphoma and rheumatoid arthritis. This reagent can help elucidate mechanisms of B cell-mediated diseases and contribute to developing targeted therapies. -
Anti-CD79B/CD3E/MS4A1 Antibody
Anafiltamig is a trivalent monoclonal antibody that targets CD79B, CD3E, and MS4A1. This innovative reagent features a humanized IgG1κ anti-CD79B component combined with a bispecific scFv fragment designed to engage CD3E and MS4A1. By simultaneously bridging T and B cells, Anafiltamig activates T cells, leading to the selective elimination of B cell tumors. This compound is particularly useful for research in B cell malignancies, including non-Hodgkin lymphoma. -
CD22 Inhibitor
GSC-718 is a synthetic sialoside and a potent inhibitor of CD22, exhibiting an IC50 value of 0.161 μM for mouse CD22. This compound is known to promote the proliferation of B cells and enhance antibody production. GSC-718 is particularly relevant for research applications involving B-cell lymphoma and autoimmune conditions such as rheumatoid arthritis. -
Anti-CD22 Antibody
RFB4 is an anti-CD22 monoclonal antibody that specifically targets the CD22 antigen, a marker commonly expressed on B-cell malignancies. This antibody can be utilized to generate recombinant immunotoxins by fusing with the pseudomonas exotoxin PE38 through disulfide linkages, such as in the construct RFB4(dsFv)-PE38. RFB4 serves as a vital tool for research focused on cancer, particularly in studies related to lymphoma and other B-cell related diseases. -
CD22 Ligand
CD22 ligand-1 is a potent and selective ligand for CD22, exhibiting a binding affinity (KD) of 0.335 µM for human CD22 and 30.7 µM for myelin-associated glycoprotein (MAG). This compound facilitates the investigation of CD22-mediated signaling pathways and holds potential for advancing research in B-cell related diseases, including autoimmune disorders and lymphomas. Its high specificity for CD22 makes it a valuable tool for understanding the role of this receptor in immunological responses. -
CD276 Monoclonal Antibody
Elfetabart is a humanized monoclonal antibody that specifically targets CD276, exhibiting notable antitumor activity. This antibody belongs to the IgG1κ isotype, making it suitable for various applications in cancer research and therapeutic development. Its interaction with CD276 plays a critical role in modulating immune responses in the tumor microenvironment, thus making it a valuable tool for studying immune evasion and developing immunotherapeutic strategies. -
CD28-B7 Inhibitor
CD28-IN-2 is a selective inhibitor of the CD28-B7 interaction, demonstrating an IC50 of 22.4 μM and a Kd value of 24.1 μM. This compound effectively inhibits CD28-mediated immune activation and prevents T cell costimulation. CD28-IN-2 serves as a valuable tool in research investigating antitumor immunity and various immune-related disorders. -
CD272 Antibody Inhibitor
Radanstobart is a humanized monoclonal antibody that selectively inhibits CD272, a checkpoint protein involved in immune regulation. This antibody exhibits significant antitumor activity, making it valuable for cancer research and immunotherapy studies. It is classified as a human IgG4κ isotype, providing a robust platform for investigating immune responses and potential therapeutic approaches targeting the tumor microenvironment. -
ICOS/CD28 Antagonist
Acazicolcept is an Fc fusion protein that serves as a dual antagonist of the inducible T cell costimulator (ICOS) and CD28. This reagent exhibits significant anti-inflammatory activity, making it valuable for research in autoimmune disorders and T cell modulation. Its unique mechanism of action positions Acazicolcept as a key tool in studying the regulation of immune responses and potential therapeutic interventions. -
B7.1-CD28 Interaction Inhibitor
B7/CD28 Interaction Inhibitor 1 is a selective inhibitor of the B7.1-CD28 interaction, exhibiting an IC50 of 50 nM. This compound disrupts T-cell costimulation, making it a valuable tool for research in immunology and cancer therapy. Its ability to modulate T-cell responses highlights its potential applications in studying immune regulation and developing immunotherapeutic strategies. -
CD28 Inhibitor
DDS5 is a selective CD28 inhibitor with an affinity (kd) of 175.57 µM, effectively disrupting the CD28-CD80 interaction with an IC50 value of 332 µM. This compound is instrumental in researching immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis, enabling investigations into immune response modulation and therapeutic strategies.
